China’s Leading CAR T-Cell Treatment Centers: Doctors and Cost Overview

CAR T-cell treatment, a major breakthrough in cancer care, has emerged as an innovative approach to deal with relapse of cancers in patients. Many countries now offer CAR T-cell treatment including the USA, India, China, Germany, France ,the UK etc. 

However, with 357 active clinical trials on CAR T-cell therapy, China has set the pace in how treatment of relapsing cancer can be changed. 

Whether it is the launching of quicker clinical trials or achieving an unprecedented success rate, its advancements in CAR T-cell therapy are not only the talk of the town but are also transforming how cancer relapse is being treated.

But what exactly is this cutting-edge therapy, and how does it work? Let’s start with the basics—because the science behind it might just surprise you.

Understanding CAR T-cell Therapy

We know that our blood has three significant components: RBC, WBC, and platelets. Our focus here is on T-lymphocytes, one of the components of WBC, which are responsible for the body’s immune defence.

In CAR T-cell treatment, these natural T-cells in your body are extracted and genetically modified in laboratories so that they can recognise cancer cells as foreign particles in your body and respond to them. 

I know this brief about CAR T–cell must have sparked interest in you. So, let’s get a quick look into the procedure to understand it in a better way.

• The first step is administration, for which some amount of blood is extracted.
• Then, in the lab, using a vector, constructs are generated to manipulate the T-cells to recognise specific cancer cells in the body.
• These newly generated constructs are biologically surface proteins known as chimeric antigen receptors or CARs.
• Then, these manipulated T cells with constructs are cryopreserved in blood banks before injecting into the blood cancer patients.

Now, here’s the real game changer! Since these cells are derived from the patient’s blood, they integrate rapidly, usually within 30 to 40 minutes, and begin to target the cancer cells and destroy them within 6 hours.

Here you can learn more about CAR T-cell treatment from Dr. Rahul Bhargava.

 

Cancers Treated with CAR T-Cell Therapy: What You Need to Know

CAR T-cell therapy is currently employed for cancers including-

• Acute Lymphoblastic Leukaemia (ALL)
• Non-Hodgkin’s lymphoma, especially diffuse large B-cell lymphoma
• Chronic Lymphocytic Leukaemia (CLL)
• Other relapsed or refractory blood cancers

Secondary Treatment Approach

CAR T-cell treatment therapy in China is often reserved for patients who have already undergone standard treatments and are employed as a last-line treatment when conventional methods fail. 

The cost of CAR-T cell therapy in China depends on factors such as type of cancer and extent of spread of tumour, which usually ranges from USD 45000 to USD 80000.

Why is China a Leading Destination for CAR T-cell?

While CAR T-cell has gained recognition across the globe for its life-saving potential, China has not only embraced it but has propelled it to new heights. 

And here’s where it gets even more impressive—by June 30, 2020, China had registered a staggering 357 CAR T-cell therapy trials, showcasing its rapid advancements in cutting-edge cancer treatment!

These robust clinical trials are complemented with other facilities listed below, making China a leading destination for CAR T-cell.

Thorough Government Support for Research

The policies in China encourage innovation in medical technology, making it possible for fast-tracked approvals for clinical trials and making China a global leader in CAR T-cell research. 

Capital Inflow for Research

The infusion of significant financial investment has hastened the development of CAR T-cell therapies. As of 2021, cell therapy companies in China had collectively raised cumulative USD 2.37 billion in funding, supplying them with the necessary resources to scale up research, infrastructure building, and scaling up clinical trials.

Increased patient demand

In the year 2022, China reported around 5 million cancer cases. This large patient demand has created an urgent need for innovative treatments, which has made China a key player in fast-paced research and trial expansions in CAR T-cell therapies.

Collaboration between hospitals and global clinical centres

With its vast network of hospitals and research institutions, China has enabled large-scale clinical trials and research. This strong collaboration enables them to recruit patients more efficiently as participants for broad data collection, aiding in the expansion of CAR T-cell therapy trials.

How much does CAR T-Cell therapy cost in China?

Advanced T-cell therapies such as CAR T-cell treatment poses greater technical difficulties compared to other oncology medications. Also, the reimbursement landscape for drugs included on China’s National Reimbursement Drug List implies that to receive CAR T-cell treatment in China,many patients will need to cover expenses themselves. The avearge cost of CAR T-cell therapy in China ranges between $ 55,000 and $ 3,50,000. The list below gives an overview of the cost of the approved CAR T-cell treatment in China.

CAR T-Cell therapy	Brand Name	Disease	Cost in China (USD)
Tisagenlecleucel	Kymriah	B-cell acute lymphoblastic leukemia (ALL)	$ 400- $ 500,000
Idecabtagene vicleucel	ABECMA®	Multiple-Myeloma	$ 400- $ 500,000
Lisocabtagene maraleucel	BREYANZI®	DLBCL	$ 300- $ 400,000
Zevorcabtagene autoleucel	Zevor-Cel	Multiple-Myeloma	$ 250- $ 300,000

Top Doctors for CAR T-cell Treatment in China

The dedication, expertise and collaborative efforts of doctors and researchers in China, along with access to cutting-edge technology and resources, have propelled both basic research and clinical applications of CAR T-cell therapy, making China emerge as a leader in clinical outcomes.

Below is the list of top CAR T-cell treatment doctors in China.

Dr. Daopei Lu

With years of experience, Dr. Lu is a renowned haematologist, who is currently serving as a Chief Scientist as well as Vice-Chairman of the Chinese Medical Association. He is a pioneer of advanced regenerative medicine, and one of the earliest applications of immunotherapy in the treatment of acute leukaemia, with excellent therapeutic results.

Dr. Peihua Peggy Lu

Dr. Peihua Peggy Lu is highly recognised haematologist and stem cell specialist with her years of expertise in managing various blood disorders. She specialises in providing CAR T-cell immunotherapy and offering other advanced cancer treatments that provide new hope for patients suffering from various blood cancers.

Dr. Tong Chunrong

A pioneer in the field of immunotherapy, Dr. Tong Chunrong is a Chief physician and Head of a scientific research institute. She is currently leading the development of CAR T-cell therapy in China and is renowned for her expertise in offering comprehensive treatment for malignant haematologic diseases such as leukaemia, lymphoma, etc.

Dr. Yajing Zhang

Currently, the Director of Hematology, Dr. Yajing Zhang, specialises in personalised cancer treatment with immunotherapy, targeted therapy, combination therapy exploration, etc. She has authored and published the first domestic “Guidelines for Managing Adverse Reactions of CAR-T Therapy for Lymphoma” and has made a remarkable contribution to CAR T-cell in China.

Dr. Zhao Defeng

With over 20 years of experience, Dr. Zhao Defeng is the Director of the Hematology Department and has extensive experience in CAR-T cell therapy and comprehensive treatment of refractory and recurrent blood cancers. He is considered as one of the best CAR T-cell doctor in China for administering over 1000 patients with CAR T-Cell therapy and has more than 25 ongoing clinical trials on it.

Leading Hospitals and Research Clinics for CAR T-cell Treatment in China

We know that implementing any new treatment for some deadly cancer should be strictly regulated and supervised. So, in order to ensure that the leading hospitals in China are following the norms and ethics for CAR T-cell therapy, the Chinese government have implemented various measures which includes:

Regulations under National Medical Products Administration (NMPA)

This body is responsible for regulating and supervising the generating, producing, and distributing CAR T-cell therapies in China. It sets standards for the quality and efficacy of CAR T-cell constructs and ensures that they meet global standards in terms of safety and efficiency. 

Clinical trial regulations

CAR T-cell is undergoing regular clinical trials regulated by the NMPA. They ensure informed consent from the patients, providing them with detailed research ideas, protecting patients’ privacy, and ensuring the safety and well-being of trial participants. 

Hospital’s Accreditation

The National Health Commission (NHC) is responsible for accrediting hospitals that offer CAR T-cell therapy. This accreditation ensures that hospitals meet certain standards for infrastructure, equipment, and adherence to national guidelines and regulations. 

Some of the top hospitals and clinics in China that offer CAR T-cell treatment are listed below. 

Peking University Cancer Hospital, Beijing

When searching for CAR T-cell treatment in China, this hospital is a top destination, known for its multidisciplinary approach to cancer care. Peking University Cancer Hospital has achieved excellent outcomes, particularly in treating relapsing blood cancers using CAR T-cell therapy.

Lu Daopei Hospital, Beijing

As a recognised name for CAR T-cell therapy in China, Lu Daopei Hospital provides cutting-edge cancer treatments, particularly in the field of haematology. The hospital has achieved significant breakthroughs in CAR T-cell therapy, treating a large number of patients with advanced blood cancers with this approach with minimal side effects.

Beijing Puhua International Hospital

With the availability of advanced immunotherapies, including CAR T-cell therapy, this hospital is known for its excellent international patient care and the use of innovative technologies to treat complex cancers.

Beijing Gobroad Boren Hospital

This hospital is recognised for its expertise in haematology and CAR T-cell therapy. It offers comprehensive diagnostic and therapeutic services for hematologic malignancies, including leukaemia, lymphoma, and multiple myeloma and associated relapsing cancer cases.

How can Vaidam Help You in Getting CAR T-cell Treatment in China? 

We understand that the CAR T-cell therapy process brings doubts and uncertainty regarding the procedure and treatment, leaving patients and their families anxious about the outcome. 

Some of the commonly asked questions include- Will the treatment be effective? What are the potential side effects? How will I cope with the physical and emotional challenges that lie ahead? 

Don’t worry. We are here to help you find leading CAR T-cell therapy clinics in China, along with additional services, including:

• Opinions from cancer specialists from China
• Elaborate explanation of the procedure and treatment outcomes
• Detailed breakdown of treatment expenses
• Travel arrangements from your country to China
• Accommodation and transportation suggestions
• Scheduling an appointment with your doctor
• Language interpretation services, if required
• Follow-ups after the CAR T-cell treatment

Vaidam Health, a globally recognised healthcare assistance company, not only facilitates your cancer treatment but also ensures that CAR T-cell therapy costs in China remain affordable. With Vaidam Health’s support, you can focus on your treatment while we handle the logistics of your medical journey to China.

Frequently Asked Questions About CAR T-cell Treatment in China

Is CAR T-cell therapy approved in China?

The National Medical Products Administration (NMPA) has approved several CAR T-cell therapies in China for relapsed B-cell acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL).

What is the Cost of CAR T-cell Therapy in China?

The cost of CAR-T cell therapy in China ranges from $ 55,000 to $ 3,50,000. If a patient is involved in clinical trials, the costs may be reduced or covered entirely.

Which countries currently offer CAR T-cell therapy for patients?

Various countries offer CAR T-cell therapy for patients suffering from relapse of certain cancers including China, USA, India, Germany, France and and the UK.

Is CAR T-cell therapy in China risky?

Like any other country, CAR T-cell therapy in China carries some risk such as neurotoxic effects, cytokine release syndrome (CRS), and some types of hematologic infections.

What is the success rate of CAR T-cell therapy in China?

The most renowned CAR-T hospitals in China have reported a high success rate in the treatment of lymphoma and leukaemia with remission rates being 50-90%. 

Which country is best for CAR T-cell therapy?

Determining the best country for CAR T-cell therapy depends on several factors, including treatment options, regulatory approvals, and access to clinical trials. China has rapidly emerged as a leader in CAR T-cell therapy, with approved number of clinical trials.